Short‐term and long‐term effect of diaphragm biofeedback training in gastroesophageal reflux disease: an open‐label, pilot, randomized trial. Issue 7 (30th July 2015)

• Record Type: Journal Article
• Authors: Sun, X.; Shang, W.; Wang, Z.; Liu, X.; Fang, X.; Ke, M.
• Is Part Of: Diseases of the esophagus. Volume 29:Issue 7(2016)
• Page Start: 829
• Page End: 836
• Publication Date: 2015-07-30
• Subjects: anti‐reflux barrier -- diaphragm biofeedback training -- gastroesophageal reflux -- manometry -- therapy; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1111/dote.12390
• Languages: English
• ISSNs: 1120-8694

Abstract

Summary: This study investigated the effectiveness of diaphragm biofeedback training (DBT) for patients with gastroesophageal reflux disease (GERD). A total of 40 patients with GERD treated at the Peking Union Medical College Hospital between September 2004 and July 2006 were randomized to receive DBT and rabeprazole proton pump inhibitor (PPI) or rabeprazole alone. The DBT + rabeprazole group received DBT during the 8‐week initial treatment; the rabeprazole group did not. During the 6‐month follow up, all patients took acid suppression according to their reflux symptoms, and the patients in the DBT + rabeprazole group were required to continue DBT. The primary outcome (used for power analysis) was the amount of acid suppression used at 6 months. Secondary outcomes were reflux symptoms, health‐related quality of life (HRQL), and esophageal motility differences after the 8‐week treatment compared with baseline. Acid suppression usage significantly decreased in the DBT + rabeprazole group compared with the rabeprazole group at 6 months ( P < 0.05). At 8 weeks, refluxs ymptoms and GERD‐HRQL were significantly improved in both groups ( P < 0.05), without difference between them. Crural diaphragm tension (CDT) and gastroesophageal junction pressure (GEJP) significantly increased in the DBT + rabeprazole group ( P < 0.05), but without change in lower esophageal sphincter (LES) pressure. There was no significant change in CDT, GEJP, and LES pressure compared with baseline in the rabeprazole group. In conclusion, long‐term DBT could reduce acid suppression usage by enhancing the anti‐reflux barrier, providing a non‐pharmacological maintenance therapy and reducing medical costs for patients with GERD.